Update on DBV Technologies' Liquidity Status and Growth Plans

Author: Caleb Price Updated: 07-28-2025 04:39 PM

Liquidity Insights from DBV Technologies

DBV Technologies, a clinical-stage biopharmaceutical company dedicated to advancing treatment options for food allergies, recently provided a comprehensive update regarding its liquidity contract with ODDO BHF. This report is an essential resource for investors and stakeholders interested in the financial health and operational efficiency of the company.

Details of the Liquidity Account

As of June 30, 2025, the liquidity account maintained under the contract with ODDO BHF consisted of:

210,069 shares of DBV Technologies.
A monetary balance totaling €171,301.08.

This balance marks a significant development since the inception of the contract on July 1, 2018, when initial assets included:

41,159 shares.
A monetary value of €432,367.25.

Trading Activity Over the Past Six Months

Between January 1, 2025, and June 30, 2025, DBV Technologies engaged in a series of trading activities, with noteworthy statistics that reflect market participation:

A total of 2,204 buy transactions.
A total of 2,398 sell transactions.

These activities amounted to significant trading volumes, consisting of:

1,156,109 shares and €1,492,280.33 on purchased shares.
1,212,908 shares and €1,556,651.52 from sales.

About DBV Technologies

DBV Technologies is at the forefront of research aimed at developing innovative solutions for food allergies and immunologic conditions that sorely need new treatments. The company's dynamic approach revolves around its proprietary technology, the VIASKIN® patch. This method utilizes epicutaneous immunotherapy (EPIT) to enhance patient tolerance to allergens.

Through this non-invasive treatment strategy, the patches deliver minuscule doses of allergens to the immune system, coming into contact with the skin to promote tolerance. This innovative approach aims to educate the immune system, ultimately leading to desensitization. DBV Technologies is fervently devoted to transforming the lives of individuals suffering from food allergies, particularly targeting young children who bear the brunt of these conditions.

The ongoing clinical trials focus on developing therapies for peanut allergies, specifically in toddlers aged 1 to 3 and children aged 4 to 7. This commitment underscores the urgency and importance of addressing food allergies in young populations.

DBV Technologies operates out of Châtillon, France, with a significant presence in North America, specifically in Warren, NJ. The company is publicly traded on Euronext Paris as DBV and on the Nasdaq as DBVT, providing investors access to its shares as it continues to grow and innovate.

Stay Connected with DBV Technologies

For further information about DBV Technologies and its innovative contributions to the biopharmaceutical landscape, visit their official website. Engage with them on their social media channels to stay updated on their ongoing projects and developments.

Frequently Asked Questions

What is the focus of DBV Technologies?

DBV Technologies focuses on developing treatment options for food allergies and other immunologic conditions.

What innovative technology does DBV utilize?

DBV utilizes its proprietary VIASKIN® patch technology that employs epicutaneous immunotherapy for delivering treatment.

How has the liquidity position evolved over time?

The liquidity position has improved significantly since the inception of the contract, reflecting ongoing market engagement and asset growth.

What are DBV’s recent trading activities?

In the first half of 2025, DBV executed over 4,600 transactions, indicating active market participation.

Where can I find more information about DBV Technologies?

More information can be found on their official website and through their social media platforms.

About The Author

Hey there I'm Caleb Price, a writer and financial specialist who loves to assist others in understanding the financial world. Having years of practical experience and a solid background in finance, my area of expertise is converting difficult financial ideas into useful, doable insights for my blog and publications. My goal with my writing is to give readers the information and assurance they need to successfully negotiate their financial journeys.

My ability to interact with a wide range of people—from novices starting their investing journey to seasoned investors looking for new approaches—has come from contributing to several financial blogs. Making money approachable and understandable is my goal; this will enable you to make wise choices and realize your financial objectives. We appreciate you coming along on this path to success and financial empowerment on Investors Hangout.

Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.